FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2774525828> ?p ?o ?g. }

• W2774525828 endingPage "2099" @default.
• W2774525828 startingPage "2099" @default.
• W2774525828 abstract "<h3>Importance</h3> Cast nephropathy is the main cause of acute kidney injury in multiple myeloma and persistent reduction in kidney function strongly affects prognosis. Strategies to rapidly remove nephrotoxic serum-free light chains combined with novel antimyeloma agents have not been evaluated prospectively. <h3>Objective</h3> To compare the hemodialysis independence rate among patients newly diagnosed with myeloma cast nephropathy treated with hemodialysis using a high-cutoff dialyzer (with very large membrane pores and high permeability to immunoglobulin light chains) or a conventional high-flux dialyzer (with small pores and lower permeability). <h3>Design, Setting, and Participants</h3> Randomized clinical trial involving 98 patients with biopsy-proven myeloma cast nephropathy requiring hemodialysis treated at 48 French centers between July 2011 and June 2016; the final date of follow-up was June 29, 2016. <h3>Interventions</h3> Intensive hemodialysis (eight 5-hour sessions over 10 days) with either a high-cutoff dialyzer (46 patients) or a conventional high-flux dialyzer (48 patients). All patients received the same chemotherapy regimen of bortezomib and dexamethasone. <h3>Main Outcomes and Measures</h3> Primary end point was hemodialysis independence at 3 months; secondary end points: hemodialysis independence rates at 6 and 12 months, hemodialysis- and chemotherapy-related adverse events, and death. <h3>Results</h3> Among 98 randomized patients, 94 (96%) (median age, 68.8 years [interquartile range, 61.2-75.3 years]; 45% women) were included in the modified intent-to-treat analysis. The hemodialysis independence rate at 3 months was 41.3% (n = 19) in the high-cutoff hemodialysis group vs 33.3% (n = 16) in the conventional hemodialysis group (between-group difference, 8.0% [95% CI, −12.0% to 27.9%],<i>P</i> = .42); at 6 months, the rate was 56.5% (n = 26) vs 35.4% (n = 17), respectively (between-group difference, 21.1% [95% CI, 0.9% to 41.3%],<i>P</i> = .04); and at 12 months, the rate was 60.9% (n = 28) vs 37.5% (n = 18) (between-group difference, 23.4% [95% CI, 3.2% to 43.5%],<i>P</i> = .02). The incidence of hemodialysis-related adverse events was 43% in the high-cutoff hemodialysis group vs 39% in the conventional hemodialysis group; chemotherapy-related serious adverse events, 39% vs 37%, respectively; and at 12 months, 9 patients vs 10 patients died. <h3>Conclusions and Relevance</h3> Among patients with myeloma cast nephropathy treated with a bortezomib-based chemotherapy regimen, the use of high-cutoff hemodialysis compared with conventional hemodialysis did not result in a statistically significant difference in hemodialysis independence at 3 months. However, the study may have been underpowered to identify an early clinically important difference. <h3>Trial Registration</h3> clinicaltrials.gov Identifier:NCT01208818" @default.
• W2774525828 created "2017-12-22" @default.
• W2774525828 creator A5001789644 @default.
• W2774525828 creator A5003490861 @default.
• W2774525828 creator A5005542946 @default.
• W2774525828 creator A5008156104 @default.
• W2774525828 creator A5013599527 @default.
• W2774525828 creator A5016941619 @default.
• W2774525828 creator A5025424518 @default.
• W2774525828 creator A5025976062 @default.
• W2774525828 creator A5026625329 @default.
• W2774525828 creator A5036173125 @default.
• W2774525828 creator A5043695215 @default.
• W2774525828 creator A5045374333 @default.
• W2774525828 creator A5050643650 @default.
• W2774525828 creator A5051532946 @default.
• W2774525828 creator A5052673276 @default.
• W2774525828 creator A5059305021 @default.
• W2774525828 creator A5059590275 @default.
• W2774525828 creator A5070014603 @default.
• W2774525828 creator A5077081397 @default.
• W2774525828 creator A5086896620 @default.
• W2774525828 creator A5088029443 @default.
• W2774525828 creator A5089880659 @default.
• W2774525828 date "2017-12-05" @default.
• W2774525828 modified "2023-10-18" @default.
• W2774525828 title "Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy" @default.
• W2774525828 cites W1159146256 @default.
• W2774525828 cites W1714859988 @default.
• W2774525828 cites W1801543025 @default.
• W2774525828 cites W1900498334 @default.
• W2774525828 cites W1966809384 @default.
• W2774525828 cites W1967300023 @default.
• W2774525828 cites W1973414229 @default.
• W2774525828 cites W1990148510 @default.
• W2774525828 cites W1994249743 @default.
• W2774525828 cites W2018049995 @default.
• W2774525828 cites W2034325115 @default.
• W2774525828 cites W2039718569 @default.
• W2774525828 cites W2041141081 @default.
• W2774525828 cites W2044436186 @default.
• W2774525828 cites W2054072744 @default.
• W2774525828 cites W2054708881 @default.
• W2774525828 cites W2073742622 @default.
• W2774525828 cites W2081128344 @default.
• W2774525828 cites W2095328443 @default.
• W2774525828 cites W2095494110 @default.
• W2774525828 cites W2099320310 @default.
• W2774525828 cites W2116218639 @default.
• W2774525828 cites W2125679118 @default.
• W2774525828 cites W2141723966 @default.
• W2774525828 cites W2146429012 @default.
• W2774525828 cites W2149024804 @default.
• W2774525828 cites W2158520275 @default.
• W2774525828 cites W2164807675 @default.
• W2774525828 cites W2239467190 @default.
• W2774525828 cites W2277498048 @default.
• W2774525828 cites W2284914514 @default.
• W2774525828 cites W2299833483 @default.
• W2774525828 cites W2347160971 @default.
• W2774525828 cites W2484473885 @default.
• W2774525828 cites W2560339482 @default.
• W2774525828 cites W2613483874 @default.
• W2774525828 doi "https://doi.org/10.1001/jama.2017.17924" @default.
• W2774525828 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5820717" @default.
• W2774525828 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29209721" @default.
• W2774525828 hasPublicationYear "2017" @default.
• W2774525828 type Work @default.
• W2774525828 sameAs 2774525828 @default.
• W2774525828 citedByCount "116" @default.
• W2774525828 countsByYear W27745258282017 @default.
• W2774525828 countsByYear W27745258282018 @default.
• W2774525828 countsByYear W27745258282019 @default.
• W2774525828 countsByYear W27745258282020 @default.
• W2774525828 countsByYear W27745258282021 @default.
• W2774525828 countsByYear W27745258282022 @default.
• W2774525828 countsByYear W27745258282023 @default.
• W2774525828 crossrefType "journal-article" @default.
• W2774525828 hasAuthorship W2774525828A5001789644 @default.
• W2774525828 hasAuthorship W2774525828A5003490861 @default.
• W2774525828 hasAuthorship W2774525828A5005542946 @default.
• W2774525828 hasAuthorship W2774525828A5008156104 @default.
• W2774525828 hasAuthorship W2774525828A5013599527 @default.
• W2774525828 hasAuthorship W2774525828A5016941619 @default.
• W2774525828 hasAuthorship W2774525828A5025424518 @default.
• W2774525828 hasAuthorship W2774525828A5025976062 @default.
• W2774525828 hasAuthorship W2774525828A5026625329 @default.
• W2774525828 hasAuthorship W2774525828A5036173125 @default.
• W2774525828 hasAuthorship W2774525828A5043695215 @default.
• W2774525828 hasAuthorship W2774525828A5045374333 @default.
• W2774525828 hasAuthorship W2774525828A5050643650 @default.
• W2774525828 hasAuthorship W2774525828A5051532946 @default.
• W2774525828 hasAuthorship W2774525828A5052673276 @default.
• W2774525828 hasAuthorship W2774525828A5059305021 @default.
• W2774525828 hasAuthorship W2774525828A5059590275 @default.
• W2774525828 hasAuthorship W2774525828A5070014603 @default.
• W2774525828 hasAuthorship W2774525828A5077081397 @default.
• W2774525828 hasAuthorship W2774525828A5086896620 @default.

• next